---
title: Xenon Pharmaceuticals Inc. (XENE)
layout: default
nav_order: 1748
---

# Xenon Pharmaceuticals Inc.
{: .fs-9 }

{: .label .label-purple }

Moat: 2/5

{: .label .label-blue }

Understandability: 4/5

{: .label .label-green }

Balance Sheet Health: 2/5

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for neurological and rare diseases.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=XENE+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/XENE/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning }
>The moat, understandability, and balance sheet health scores reflect a conservative evaluation to ensure a margin of safety in any assessment.



{: .important }
**Moat Analysis: 2/5**
Xenon's moat is weak and rated a 2/5, primarily due to the inherent risks and long timelines in pharmaceutical development. It relies on its specialized knowledge and novel technologies to create treatments for conditions that currently have few options. However, this is not sufficient to create a wide moat. The value of pharmaceutical companies is largely tied to their patents which expire relatively quickly, leaving them exposed to competition from generic drugs. This is not to say that these products do not have value. They just have value for limited periods of time. 
*   **Intangible Assets:** Xenon owns intellectual property that is primarily dependent on a limited number of patents related to their drug discoveries. While they are important for temporary protection, they are not long-lasting.
*   **Switching Costs:** Switching costs for the end-customers of Xenon's products (patients) are generally low. Therefore, the risk of alternatives is always present, limiting pricing power.
*   **Network Effects:** No network effects are present in Xenon’s business model.
*   **Cost Advantages:** Xenon does not possess any unique cost advantages. 

{: .warning }
**Legitimate Risks to the Moat and Business Resilience**
*   **Clinical Trial Failures:** The biggest risk is failure in clinical trials, that may result in loss of investment and delayed approval.
*   **Regulatory Hurdles:** Stringent regulatory standards from FDA and other governmental agencies may delay or prevent a product from reaching the market.
*   **Patent Challenges:** Patents for their drugs can be challenged or circumvented by other companies.
*   **Competition:** Competitors with larger R&D budgets can be a formidable threat and a risk in the long-term.
*   **Financing Risks:** Xenon is a clinical-stage company that requires constant funding. Any trouble in raising capital, or additional dilution, can negatively affect shareholders.
*   **Commercialization Challenges:** Xenon is developing treatments for rare diseases. Because the markets are small and require a dedicated sales force, this can impact profitability.

Xenon’s business model is tied to the successful development and commercialization of a limited number of drugs, the main risk comes from the long drug development processes that pharmaceutical companies undergo.
Even with a well-defined process of drug development, clinical trials can fail. Clinical trials can become expensive, therefore many smaller pharmaceutical companies such as Xenon have to depend on investors, if there is any trouble in raising capital, it can derail further clinical trials.
In the pharmaceutical industry, especially one like XENE that is focused on rare diseases, it is critical to make sure you can prove to regulators that your product is both safe and effective. Furthermore, this process is very time and money-consuming.
To summarise, the risks come from an extensive research and development process where there is no guarantee for success and limited patent protection.
With that said, XENE has a good pipeline, focusing on many unique and new drugs, that are showing very positive results in early trials, giving them the ability to achieve success in the long-term.

**Business Description:**
*   **Revenue Distribution:** As a clinical-stage company, XENE currently has no product revenues. Its income is mostly derived from collaborations and license agreements. In the 10-Q filings, collaboration revenues account for a majority of the revenue, however, it can vary a lot between the periods.
*   **Industry Trends:** The biopharmaceutical industry is undergoing substantial change, with an increased focus on specialty drugs, treatments for rare diseases, and targeted therapies. Regulatory agencies have become faster at assessing and approving the drugs and this trend will only continue into the future. There is also an increasing emphasis on the real-world data for better product efficacy and safety.
*   **Margins:** As a clinical-stage company, Xenon's main expenses are research and development along with general and administrative costs. They have no gross margin or operating margin.
*   **Competitive Landscape:** XENE operates in a competitive market with established pharmaceutical giants, as well as smaller biotechnology firms. Although the market has different players, they target different aspects of drug development and also compete on a geographical scale. 
*   **What Makes the Company Different:** Xenon is focused on precision medicine, which attempts to target the genetic and biological cause of disease.
{: .important }
It uses proprietary technologies and expertise to develop novel treatments for the diseases they are targeting and works on multiple new drugs at a time, increasing the chances of achieving success. The company is actively engaged in various research partnerships and collaborations to achieve its goals. This collaboration with partners gives a unique insight into specialized fields, and helps the company to be more efficient at its drug development.
*   **Other Relevant Factors:**  The focus is on diseases that are known to have complex genetic underpinnings, allowing them to develop drugs with a higher chance of having success. They have also established a solid pipeline, as discussed above.

**Financials in-depth:**
{: .note }
Key things to focus on: The company is in pre-revenue state, so the financial analysis has to focus on how well is the company funding its operations.

Xenon Pharmaceuticals is a clinical-stage company and has no revenue from products. It relies on collaboration agreements and licenses to generate revenues. As a result, the revenue numbers are not predictable, and can vary significantly quarter to quarter.
*   **Revenue:** It reports total revenues of $2.9 million for the three months ending September 30, 2023 which is down by 49% from $5.7 million in 2022. For the nine months ending on September 30 2023, revenues came in at $16.8 million, compared to $22 million from last year. The bulk of revenue is attributable to collaboration revenues. In all recent reports, XENE has reported operating expenses to be more than the revenue it generates. 
*   **Operating Expenses:** XENE's expenses are mostly in R&D and General and administrative Expenses. R&D expenses for the most recent quarter stood at $44 million, an 18% increase YoY. General and admin expenses came in at $17.8 million, up 27.2% YoY. For the nine-month period, R&D expenses are $114.5 million compared to $78.9 million in the same period last year. G&A expenses have grown from $43.5 million to $52.4 million. 
*   **Net Income:** The net loss for the three months was $57.8 million, compared to the loss of $54.5 million in the same period of last year. The net loss for the nine months ending September 2023 was 162.3 million, compared to 146.9 million in 2022.
*   **Liquidity:** As of September 30, 2023, XENE has 390.2 million in cash, cash equivalents, and marketable securities. They have a cash flow burn of $162.3 million in 9 months. Although, the company is not yet generating revenue from the sale of its drugs, it has sufficient cash to continue its operations for at least another 2 years.
*   **Debt:** XENE has no debt. 

The financial situation for XENE can be described as good-looking in the short-term because of strong levels of cash, but as long as they remain clinical stage, their financial risks will be high, due to high levels of cash burn, as well as dependence on external financing.

{: .note }
**Recent Concerns and Management's View**
On the Q3 2023 earnings call, CEO Ian Mortimer said:  “Our near-term priorities will be to deliver meaningful clinical data on our clinical stage candidates and advance our ongoing regulatory engagements”. He reiterated the three key milestones for the company moving forward. First is to focus on the development of XEN901 for severe seizure disorder. Second is to continue to develop XEN1101 for the treatment of major depressive disorder. Third is to advance their novel pipeline.
They have acknowledged the fact that they are depending on outside investors and that is what they are working towards.
Although their current financial situation is stable, there has been some pushback on a recent offering, with shareholders feeling that they are diluting the stock by continuing to take on more investment. The CEO has responded to that on the earnings call by saying that the company will maintain fiscal discipline and will only do what is best for all shareholders.
A common concern among smaller biotech companies is the possibility of takeover from larger companies, and this has not been mentioned specifically on XENE's financial statements and earnings calls, it does not seem like an immediate danger to XENE.

**Understandability: 4/5**
Xenon's business is focused on a specific sector—biopharmaceuticals—that makes the fundamental business model easy to understand. However, clinical trials and their associated risks, regulations, as well as financial details are complicated, especially given the company’s current financial position. Therefore the understandability rating will be 4/5.

**Balance Sheet Health: 2/5**
Xenon is a clinical-stage biopharmaceutical company, and as such, the company spends more than it makes in revenue. The company has $390.2 million in cash, and no debt, but due to continued cash burn, the financial situation can become shaky. Thus the rating is a 2/5.
